Independent clinical research center City of Hope has secured $50m fund from the Ashley Furniture Industries, owner, Wanek family which will support in developing remedy for type 1 diabetes (T1D) within six years.

Under the research project led by City of Hope, series of highly-focused programmes will be created which will use an integrated approach to cure T1D, including immunotherapy approaches, as well as research into beta cell transplantation and addressing resistance of the body for insulin secreting cells.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

City of Hope president and CEO Robert Stone said: "City of Hope is extremely grateful for the Wanek family's significant gift that will enable the institution to forward type 1 diabetes research, the results of which will have worldwide impact.

“We invite others to join the Wanek family and City of Hope as we continue to move even closer to a cure for type 1 diabetes."

It will mainly focus on immune modulation which involves triggering the immune system's role in diabetes, including T cell modulation and stem-cell based therapies that have the potential to reverse the auto-immune attack on islet cells in the pancreas, which is the cause of T1D.

Researchers will rejuvenate insulin secreting beta cells as well as imaging them, to encourage long-term survival. Depreciation of these beta cells is responsible for both Type 1 and type 2 diabetes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The programmes will also explore ways to address complications such as accelerated heart, kidney, neural and eye diseases which are associated with both T1D and T2D.

It will work on the genetic level to reverse complications and find ways to predict the development of complications.